AI-generated analysis. Always verify with the original filing.
Erasca, Inc. announced financial results for Q4 and full year 2025, reporting net loss of $29.1 million ($0.10 per share) and $124.5 million ($0.44 per share), respectively, with cash of $341.8 million as of December 31, 2025, and pro forma cash of $434 million expected to fund operations into H2 2028. The company highlighted promising early clinical data for ERAS-0015, expanded licensing rights, and completed a $259 million upsized financing.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 12, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months an
Financial Statements and Exhibits. Exhibit Description 99.1 Press Release issued March 12, 2026 104 Cover Page Interactive Data File SIGNATURES Pursuant to the